Related Experiment Videos
[Epidermal growth factor receptors (EGFR): a new target for anticancer therapy]
M Gainet1, E Guardiola, A Dufresne
1Service d'oncologie, CHU Jean-Minjoz, boulevard Fleming, 25030 cedex, Besançon, France. mgainet@chu-besancon.fr <mgainet@chu-besancon.fr>
Abstract:
Epidermal Growth Factor receptor (EGFR) are a key factor for the tumoral proliferation and its tumoral over expression appears to be a powerful prognosis factor. Currently, 2 types of treatments are targeting EGFR: a monoclonal antibodies anti-EGFR and a specific inhibitors of the EGFR tyrosine kinase. The administration of these compound alone or in combination with chemotherapy gives some promising results. These targets as anti-cancer therapy had emerged to be a new perspective for oncology.